Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 May;134(5):561-7.
doi: 10.1007/s00432-007-0319-5. Epub 2007 Oct 16.

Low nuclear grade but not cell proliferation predictive of pathological complete response to docetaxel in human breast cancers

Yasuo Miyoshi  1 , Masafumi Kurosumi, Junichi Kurebayashi, Nariaki Matsuura, Masato Takahashi, Eriko Tokunaga, Chiyomi Egawa, Norikazu Masuda, Seung Jin Kim, Masatsugu Okishiro, Tetsu Yanagisawa, Satsuki Ueda, Tetsuya Taguchi, Yasuhiro Tamaki, Shinzaburo Noguchi; Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society
Affiliations

Low nuclear grade but not cell proliferation predictive of pathological complete response to docetaxel in human breast cancers

Yasuo Miyoshi et al. J Cancer Res Clin Oncol. 2008 May.

Abstract

Purpose: Predictive factors for response to docetaxel in human breast cancers have yet to be identified. The aim of the present study was to investigate the relationship of various clinicopathological and biological parameters with pathological response to docetaxel in the neoadjuvant setting.

Methods: The study population comprised 78 patients with primary breast cancers who were treated with docetaxel [60 mg/m(2); four (median) cycles, range 3-6; q3w] as neoadjuvant therapy and subsequently treated with mastectomy or breast conserving surgery. Tumor samples obtained before chemotherapy were subjected to histological examination and immunohistochemistry of HER-2 and Ki-67.

Results: The pathological complete response (pCR) rate was significantly (P=0.04) higher for tumors with low nuclear grade (NG-I or -II) (21%) than for tumors with high NG (NG-III) (5%). The pCR rate (20%) of small (<or=5 cm) tumors was marginally significantly (P=0.05) higher than that of large (>5 cm) tumors (5%). Combined analysis of NG and tumor size showed that low-NG small tumors have a higher response rate (30%) than high-NG small tumors (11%; P=0.13), low-NG large tumors (11%; P=0.15), and high-NG large tumors (0%; P=0.009). No statistically significant association was observed between pCR rate and menopausal status, lymph node status, ER, PR, HER-2, or Ki-67.

Conclusions: Low nuclear grade, but not cell proliferation determined by Ki-67, is associated with a good pathological response to docetaxel. Combination of low nuclear grade and small tumor size may be useful for the selection of breast tumors with a high pCR rate (30%).

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Immunohistochemical staining of HER-2 and Ki-67 (×400). Strong membranous staining of HER-2 was detected in b but none in a. High and low frequency of nuclear positivity for Ki-67 were detected in d and c, respectively
Fig. 2
Fig. 2
Pathological complete response (pCR) rates of tumors according to nuclear grade and tumor size
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Amat S, Bougnoux P, Penault-Llorca F, Fetissof F, Cure H, Kwiatkowski F, Achard JL, Body G, Dauplat J, Chollet P (2003) Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate. Br J Cancer 88:1339–1345 - PMC - PubMed
    1. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerham DL, Wolmark N, National Surgical Adjuvant Breast, Bowel Project Protocol B-27 (2003) The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21:4165–4174 - PubMed
    1. Bottini A, Berruti A, Bersiga A, Brizzi MP, Brunelli A, Gorzegno G, DiMarco B, Aguggini S, Bolsi G, Cirillo F, Filippini L, Betri E, Bertoli G, Alquati P, Dogliotti L (2000) p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clin Cancer Res 6:2751–2758 - PubMed
    1. Burcombe RJ, Makris A, Richman PI, Daley FM, Noble S, Pittam M, Wright D, Allen SA, Dove J, Wilson GD (2005) Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer 92:147–155 - PMC - PubMed
    1. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, O’Connell P (2003) Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362:362–369 - PubMed

Publication types